

# Ontario Public Drug Programs Drug Submission Status

---

**Generic Name:** pazopanib hydrochloride  
**Brand Name:** Votrient  
**Strength:** 200mg tablet  
**Manufacturer:** GlaxoSmithKline Inc.  
**Indication:** The treatment of patients with metastatic renal cell carcinoma  
**Rapid Review:** Not requested

Submission Type:	Date Submission Received:	Date Submission Deemed Complete:	Review Status:	Funding Decision:
First Review (Initial Submission)	27/07/2011	22/08/2011	EO decision rendered	Funding considered through the Exceptional Access Program (EAP)
Reconsideration (Resubmission #1)	01/11/2012	19/12/2012	EO decision rendered	Funding criteria expanded beyond the current criteria under Exceptional Access Program (EAP)

## Rapid Review:

Details of the Rapid Review process can be found at:

[www.health.gov.on.ca/en/pro/programs/drugs/drug\\_submissions/rapid\\_review\\_process.aspx](http://www.health.gov.on.ca/en/pro/programs/drugs/drug_submissions/rapid_review_process.aspx)

## Review Status:

- Screening – Ministry is screening the manufacturer’s submission to ensure all regulatory and policy requirements have been met in order to proceed with the drug review.
- Submission incomplete – Manufacturer did not meet the necessary requirements to allow review to proceed.
- Submission complete & under review – Manufacturer met all requirements to proceed with the drug review, and evaluation of the drug submission is underway.
- Committee to Evaluate Drugs (CED) review completed, manufacturer requesting reconsideration – A recommendation was made by the CED, however the manufacturer has submitted or will be submitting additional information.
- Committee to Evaluate Drugs (CED) review completed – A recommendation was made by the CED.
- Executive Officer (EO) decision rendered.

## Funding Status:

The Committee to Evaluate Drugs (CED) recommendation and the Executive Officer (EO) decision, if available, can be found at:

[www.health.gov.on.ca/en/pro/programs/drugs/ced\\_rec\\_table.aspx](http://www.health.gov.on.ca/en/pro/programs/drugs/ced_rec_table.aspx)

Updated: January 23, 2014